Rare Disease Report

Myeloproliferative Neoplasms

Positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of fostamatinib disodium hexahydrate (Tavalisse) were published in the American Journal of Hematology this week.
The FDA approved fostamatinib disodium hexahydrate (Tavalisse) tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia. RDR discusses with Dr James Bussel.
Rigel announced that the U.S. FDA approved fostamatinib disodium hexahydrate (Tavalisse) tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia.
Rare Disease Report tries to keep its audience at the forefront with the latest news from the hematological and oncological spaces. This new infographic provides 5 little-known facts about MPNs that might not necessarily be covered in news articles from RDR or other media outlets.
Results from the Phase 3 PERSIST-2 clinical trial of the investigational JAK2 inhibitor pacritinib have been published online in The Journal of the American Medical Association (JAMA) Oncology.
Biopharmaceutical company Incyte has partnered with Academy Award winning filmmaker Cynthia Wade to develop a series of short documentary films to raise awareness for MPNs.
The ipsogen JAK2 RGQ PCR Kit  received clearance from the U.S. FDA for additional use in the diagnosis of all myeloproliferative neoplasms.
New research published in Annals of Internal Medicine shows that the rate of arterial and venous thrombosis was significant in patients with myeloproliferative neoplasms (MPNs).
New research published in Annals of Internal Medicine shows that the rate of arterial and venous thrombosis was significant in patients with myeloproliferative neoplasms (MPNs).
Emmaus Life Sciences has announced that Endari, a medication developed to reduce acute complications in patients with sickle cell disease, is now available by prescription in the United States.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.